BioStock: Scandion Oncology strengthens executive leadership
As its clinical development program intensifies, Scandion Oncology can start planning for its next phase of the company development and clinical trials of its top candidate, SCO-101, in metastatic colorectal cancer. This means the company is ready to transition into its next phase of development, and it took a major step in that direction by appointing Bo Rode Hansen to the position of CEO. BioStock reached out to the new CEO to learn more about what’s in store for Scandion Oncology in the months to come.
Read the full interview with Bo Rode Hansen, CEO of Scandion Oncology, at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se